The biotech said it would halt development of its alpha-1 antitrypsin deficiency (AATD) drug after VRTX said it likely wouldn't have real clinical benefits for those suffering from the rare genetic disease. Vertex Pharmaceuticals (VRTX, -11.0%) was another notable decliner today. SEE MORE 20 Dividend Stocks to Fund 20 Years of Retirement That said, the latest inflation data "likely does little to change the Fed's timetable for tapering asset purchases," says Ryan Detrick, chief market strategist at LPL Financial.